Baidu
map

京津冀三省市医疗协作发展:他们这样“造血”

2019-04-02 李嘉瑞 新华社

每周五,北京安贞医院的医生王苏都会赶到河北省唐山市曹妃甸区医院,为这里的心血管内科患者做一天手术。从2016年7月至今,从未间断。起初,他只是来诊治疑难杂症。时间久了,当地医生跟着王苏,医术也得到了提升。在京津冀三省市的医疗协作中,这种从“输血式”走向“造血式”的转变已经越来越多。“以前本地做不了支架手术。”曹妃甸区医院心血管内科主任孙春霞介绍,患者只能转到唐山市医院治疗。不仅耽误病情,还要支出更

每周五,北京安贞医院的医生王苏都会赶到河北省唐山市曹妃甸区医院,为这里的血管内科患者做一天手术。从2016年7月至今,从未间断。起初,他只是来诊治疑难杂症。时间久了,当地医生跟着王苏,医术也得到了提升。在京津冀三省市的医疗协作中,这种从“输血式”走向“造血式”的转变已经越来越多。

“以前本地做不了支架手术。”曹妃甸区医院血管内科主任孙春霞介绍,患者只能转到唐山市医院治疗。不仅耽误病情,还要支出更多的费用。

两年多来,王苏不仅自己做手术,还对曹妃甸区医院心血管内科的医生悉心指导。曹妃甸区医院副院长孙善卫介绍,在京冀两地的医疗协作下,曹妃甸的医生还分批到北京安贞医院、阜外医院学习。

北京市发改委相关负责人介绍,北京市注重从单方面“输血式”共建,向联合津冀推动当地公共服务提升水平的“造血式”转变,合力提升区域基本公共服务均等化水平。

北京通州潞河医院临近河北省的“北三县”,接诊的患者中来自“北三县”的曾经高达30%至40%。京津冀三省市医疗协作逐步展开之后,潞河医院帮助“北三县”的医院建立急救体系,先后派出支援医务人员550余人次。

这仍然是“输血式”的医疗协作,真正让潞河医院院长纪智礼自豪的,是“造血式”的医疗协作。潞河医院的医生们正在调研当地土壤和水质问题。纪智礼说,通州和“北三县”水土相连,很多疾病也是类似的,希望通过三至五年的时间把当地的土壤、水质等环境因素研究清楚,然后协同环保、疾控等部门做出进一步改善。

北京威努特技术有限公司是一家来自北京中关村的高科技企业,已经落户在天津滨海新区。公司负责人王方立说,通过北京、天津的共建共管,公司员工的医疗等问题都得到了解决,公司也有信心在滨海长期发展下去。

国家发改委相关负责人介绍,京津冀三省市医疗卫生协作紧密。北京市17家医院与河北省唐山市、张家口市、保定市等地的医院建立合作关系,三省市推进双向转诊和检查检验结果互认,推动组建跨区域医联体,联合培养高端医学人才,33项临床检验结果在京津冀296家医疗机构实现互认,20项医学影像检查结果在155家医疗机构实行共享。

此外,在京医院帮扶河北建立13家区域医疗中心。医疗保险转移接续和异地就医服务取得重要进展,河北燕达医院实现异地就医直接持卡结算,三省市新农合信息平台完成对接。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1659911, encodeId=a3f916599113e, content=<a href='/topic/show?id=ae13245e16c' target=_blank style='color:#2F92EE;'>#京津冀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24571, encryptionId=ae13245e16c, topicName=京津冀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7e25082405, createdName=achengzhao, createdTime=Tue Oct 22 10:30:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494669, encodeId=31db1494669db, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Apr 04 14:30:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364088, encodeId=e4a13640885f, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Thu Apr 04 05:29:23 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364048, encodeId=fac6364048e9, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Wed Apr 03 08:46:08 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364042, encodeId=52da3640422e, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Apr 03 07:16:53 CST 2019, time=2019-04-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1659911, encodeId=a3f916599113e, content=<a href='/topic/show?id=ae13245e16c' target=_blank style='color:#2F92EE;'>#京津冀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24571, encryptionId=ae13245e16c, topicName=京津冀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7e25082405, createdName=achengzhao, createdTime=Tue Oct 22 10:30:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494669, encodeId=31db1494669db, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Apr 04 14:30:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364088, encodeId=e4a13640885f, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Thu Apr 04 05:29:23 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364048, encodeId=fac6364048e9, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Wed Apr 03 08:46:08 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364042, encodeId=52da3640422e, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Apr 03 07:16:53 CST 2019, time=2019-04-03, status=1, ipAttribution=)]
    2019-04-04 俅侠
  3. [GetPortalCommentsPageByObjectIdResponse(id=1659911, encodeId=a3f916599113e, content=<a href='/topic/show?id=ae13245e16c' target=_blank style='color:#2F92EE;'>#京津冀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24571, encryptionId=ae13245e16c, topicName=京津冀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7e25082405, createdName=achengzhao, createdTime=Tue Oct 22 10:30:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494669, encodeId=31db1494669db, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Apr 04 14:30:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364088, encodeId=e4a13640885f, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Thu Apr 04 05:29:23 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364048, encodeId=fac6364048e9, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Wed Apr 03 08:46:08 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364042, encodeId=52da3640422e, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Apr 03 07:16:53 CST 2019, time=2019-04-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1659911, encodeId=a3f916599113e, content=<a href='/topic/show?id=ae13245e16c' target=_blank style='color:#2F92EE;'>#京津冀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24571, encryptionId=ae13245e16c, topicName=京津冀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7e25082405, createdName=achengzhao, createdTime=Tue Oct 22 10:30:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494669, encodeId=31db1494669db, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Apr 04 14:30:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364088, encodeId=e4a13640885f, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Thu Apr 04 05:29:23 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364048, encodeId=fac6364048e9, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Wed Apr 03 08:46:08 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364042, encodeId=52da3640422e, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Apr 03 07:16:53 CST 2019, time=2019-04-03, status=1, ipAttribution=)]
    2019-04-03 龙胆草

    学习谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1659911, encodeId=a3f916599113e, content=<a href='/topic/show?id=ae13245e16c' target=_blank style='color:#2F92EE;'>#京津冀#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24571, encryptionId=ae13245e16c, topicName=京津冀)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7e25082405, createdName=achengzhao, createdTime=Tue Oct 22 10:30:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494669, encodeId=31db1494669db, content=<a href='/topic/show?id=084d9499599' target=_blank style='color:#2F92EE;'>#造血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94995, encryptionId=084d9499599, topicName=造血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=caed9138962, createdName=俅侠, createdTime=Thu Apr 04 14:30:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364088, encodeId=e4a13640885f, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Thu Apr 04 05:29:23 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364048, encodeId=fac6364048e9, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Wed Apr 03 08:46:08 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364042, encodeId=52da3640422e, content=谢谢了,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Apr 03 07:16:53 CST 2019, time=2019-04-03, status=1, ipAttribution=)]
    2019-04-03 txqjm

    谢谢了,学习

    0

相关资讯

医教研三位一体 京津冀+皮肤科协作网助推医疗均质化

皮肤病的发病率是100%,但皮肤科医生的诊疗水平参差不齐,与满足人们日益增长的医疗需求还存在一定的距离。旨在解决这一问题的“京津冀+皮肤科协作网”(下称“协作网”)近日在北京启动,由北京大学第一医院(下称“北大医院”)协同全国40家三级甲等教学医院和80家基层医院联合发起,希望使我国皮肤病诊疗水平更加均质化、优质化、规范化。民众缺少正确的皮肤知识“皮肤位于体表,因此皮肤病的临床表现多位于肌肤暴露部

从医药分开到医保结算 京津冀吉辽晒医改好经验

12月22日,国家卫生健康委员会在北京召开新闻发布会。会上,北京市卫生健康委主任雷海潮、北京市西城区政府副区长郁治、天津市蓟州区政府副区长王俊茹、河北省黄骅市政府市长宋忠秋、辽宁省辽阳市政府副市长原阳、吉林省白城市政府副市长梁仰椿分别介绍各地有关深化医改工作的典型经验。北京医药分开综合改革成效显着“2017年3月,北京市政府印发《医药分开综合改革实施方案》,改革实施以来,迈出坚实步伐,发生积极

天津市市长张国清:探索京津冀异地就医门诊联网直接结算

天津市市长张国清14日表示,2019年,天津将积极主动推进京津冀协同发展,加快“通武廊”一体化改革,探索京津冀异地就医门诊联网直接结算。天津市第十七届人民代表大会第二次会议14日开幕。张国清作《政府工作报告》时介绍,过去一年,天津全力落实京津冀协同发展重大国家战略,主动服务雄安新区建设发展,着力推进产业协同、创新协同、体制机制协同、环保协同、基础设施建设协同等“五个协同”。天津积极承接北京非首都功

京津冀采血一体化 下一站在哪

尽管京津冀三地联合做了一些工作,但仅处于初级阶段。

京津冀医疗费用减负初现成效 每年可节省8亿元

医用耗材费用虚高一直是患者看病贵的重要原因,也是医改过程中难啃的硬骨头。5月30日,京津冀三地卫生计生委在天津召开发布会,通报了京津冀三地公立医院医用耗材将实行联合采购工作的完成情况,采购结果将于6月30日起正式执行。

京、津、冀三地中药炮制规范比较研究

为中药饮片市场监管提供技术支持,方便京、津、冀三地百姓就医用药。

Baidu
map
Baidu
map
Baidu
map